Association of adiponectin (ADIPOQ) rs2241766 polymorphism and dyslipidemia in HIV/HCV-coinfected patients

• Published in: European journal of clinical investigation Vol. 44; no. 5; pp. 453 - 462
• Main Authors: Pineda-Tenor, Daniel, Berenguer, Juan, García-Broncano, Pilar, Jiménez-Sousa, María A., Fernández-Rodríguez, Amanda, Diez, Cristina, García-Álvarez, Mónica, Carrero, Ana, Catalán, Pilar, Aldámiz-Echevarria, Teresa, Resino, Salvador
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01-05-2014
• Subjects: Adiponectin; Adiponectin - genetics; Adult; AIDS; Cholesterol, HDL - metabolism; Cholesterol, LDL - metabolism; chronic hepatitis C; Coinfection; Cross-Sectional Studies; dyslipidemia; Dyslipidemias - genetics; Female; Hepatitis C virus; Hepatitis C, Chronic - complications; HIV Infections - complications; Human immunodeficiency virus; Humans; Insulin Resistance - genetics; Male; metabolic disturbance; Polymorphism, Genetic - genetics; SNPs; Triglycerides - metabolism; SNPs; metabolic disturbance; AIDS; dyslipidemia; chronic hepatitis C; Adiponectin
• ISSN: 0014-2972; 1365-2362
• DOI: 10.1111/eci.12250

Background
The adiponectin (ADIPOQ) rs2241766 polymorphism is related to metabolic abnormalities. The aim of this study was to evaluate the association of the ADIPOQ rs2241766 polymorphism with serum dyslipidemia and insulin resistance (IR) in human immunodeficiency virus (HIV)/hepatitis C virus (HCV)‐coinfected patients.
Methods
We carried out a cross‐sectional study on 262 patients. ADIPOQ rs2241766 polymorphisms were genotyped by GoldenGate® assay. Generalized linear models (GLMs) were used to compare continuous outcome variables (total cholesterol (TC), triglycerides (TG), low‐density lipoprotein cholesterol (LDL‐C), high‐density lipoprotein cholesterol (HDL‐C), non‐HDL‐C and homeostatic model assessment (HOMA)) and categorical outcome variables (TC ≥ 200 mg/dL, TG ≥ 170 mg/dL, LDL‐C ≥ 100 mg/dL, HDL‐C ≤ 35 mg/dL, non‐HDL‐C ≥ 120 mg/dL and HOMA ≥ 3·8) according to ADIPOQ genotype under a dominant inheritance model.
Results
Patients with the rs2241766 GG/GT genotype had significantly lower serum TC levels (P = 0·038) and percentages of TC ≥ 200 mg/dL (P = 0·022) than rs2241766 TT carriers. When adjusted GLM was performed, rs2241766 GG/GT was associated with low serum TC levels (arithmetic mean ratio (AMR) = 0·92 [(95% CI = 0·85; 0·99) P = 0·024]) and low likelihood of TC ≥ 200 mg/dL (odds ratio (OR) = 0·32 [(95% CI = 0·11; 0·88) P = 0·027]. When stratifying by steatosis, no significant values were found for patients without steatosis. However, for patients with steatosis, rs2241766 GG/GT genotypes were related to low TC serum values of TC (AMR = 0·89; P = 0·027), LDL‐C (AMR = 0·85; P = 0·039) and non‐HDL‐C (AMR = 0·86; P = 0·015). No significant associations were found between rs2241766 and HOMA values.
Conclusions
The presence of the ADIPOQ rs2241766 G allele (GG/GT genotype) was associated with a protective effect against dyslipidemia, primarily in HIV/HCV‐coinfected patients with steatosis.